The estimated Net Worth of Sean Bohen is at least $3.61 Milion dollars as of 20 November 2023. Dr Bohen owns over 57,225 units of Olema Pharmaceuticals stock worth over $1,788,375 and over the last 4 years he sold OLMA stock worth over $824,040. In addition, he makes $999,300 as Pres i CEO & Director at Olema Pharmaceuticals.
Dr has made over 6 trades of the Olema Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 57,225 units of OLMA stock worth $824,040 on 20 November 2023.
The largest trade he's ever made was selling 57,225 units of Olema Pharmaceuticals stock on 20 November 2023 worth over $824,040. On average, Dr trades about 10,807 units every 105 days since 2020. As of 20 November 2023 he still owns at least 144,925 units of Olema Pharmaceuticals stock.
You can see the complete history of Dr Bohen stock trades at the bottom of the page.
Dr. Sean P. Bohen M.D., Ph.D. is the Pres, CEO & Director at Olema Pharmaceuticals.
As the Pres i CEO & Director of Olema Pharmaceuticals, the total compensation of Dr D at Olema Pharmaceuticals is $999,300. There are no executives at Olema Pharmaceuticals getting paid more.
Dr D is 54, he's been the Pres i CEO & Director of Olema Pharmaceuticals since . There are 2 older and 5 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
Sean's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham oraz Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: